PLRX (Pliant Therapeutics) Construction In Progress: $0.15 Mil (As of Mar. 2026)


PLRX Pliant Therapeutics Inc PLRX
31 GF Score
Price $1.14
! 2 Warning Signs
View Full Analysis

What is Pliant Therapeutics Construction In Progress?

Pliant Therapeutics PLRX +0.88% 31 Construction In Progress is $0.15 Mil as of Mar. 2026. GuruFocus rates PLRX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Pliant Therapeutics's quarterly construction in progress declined from Sep. 2025 ($0.15 Mil) to Dec. 2025 ($0.15 Mil) but then stayed the same from Dec. 2025 ($0.15 Mil) to Mar. 2026 ($0.15 Mil).

Pliant Therapeutics's annual construction in progress increased from Dec. 2023 ($0.05 Mil) to Dec. 2024 ($0.35 Mil) but then declined from Dec. 2024 ($0.35 Mil) to Dec. 2025 ($0.15 Mil).

Pliant Therapeutics Construction In Progress Historical Data

* Premium members only.

The historical data trend for Pliant Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pliant Therapeutics Construction In Progress Chart

Pliant Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial 0.04 0.07 0.05 0.35 0.15

Pliant Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.15 0.15 0.15 0.15
PLRX
31GF Score
Pliant Therapeutics Inc PLRX
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pliant Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.15 Mil mean?
Pliant Therapeutics (PLRX) has a Construction In Progress of $0.15 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Pliant Therapeutics and its competitors.
Is Pliant Therapeutics' Construction In Progress too high?
Pliant Therapeutics' current Construction In Progress is $0.15 Mil. Overall, Pliant Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pliant Therapeutics' Construction In Progress compare to RLYB and LIXT?
Pliant Therapeutics' Construction In Progress of $0.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Pliant Therapeutics and its competitors. Pliant Therapeutics's current Construction In Progress is $0.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pliant Therapeutics stock overvalued right now?
Pliant Therapeutics (PLRX) has a current Construction In Progress of $0.15 Mil. The current Construction In Progress is $0.15 Mil. Pliant Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Pliant Therapeutics (PLRX), the current Construction In Progress is $0.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pliant Therapeutics Business Description

Other Exchanges 9PT:Germany
Address 331 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
31GF Score

Get the complete analysis for PLRX

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.14
Price